← 홈

Antibody · 난소암

93개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 93개
AntibodystaleKite, A Gilead CompanyPhase 1

Lenzilumab (Lenzilumab)

Relapsed/Refractory Large B-cell Lymphoma · FRα

#FR#Antibody#Phase1#항체#면역항체+4
효능 ORR 9.9%임상시험 6상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 2

Vudalimab (Vudalimab)

Ovarian Cancer; Clear Cell Carcinoma · Castration-Sensitive Prostate Carcinoma

#Castration-SensitiveProstateCarc#Antibody#Phase2#항체#면역항체+4
임상시험 5상태 DISCONTINUED
AntibodystaleRochePhase 2

131I-rituximab (131I-rituximab)

Relapsed or Refractory Follicular Lymphoma or Mantle Cell Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
임상시험 4상태 ACTIVE
AntibodystaleSutro Biopharma, Inc.Phase 3

Luveltamab tazevibulin (Luveltamab tazevibulin)

Ovarian Cancer; Epithelial Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase3#항체#면역항체+3
임상시험 3상태 DISCONTINUED
AntibodyRochePhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+carboplatin±bevacizumab)

Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+4
임상시험 3상태 RECRUITING
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Actinium Ac 225-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cetuximab + Irinotecan (Cetuximab + Irinotecan)

Advanced Colorectal Cancer · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 2.081%임상시험 2상태 ACTIVE
AntibodystaleJanssenPhase 1

daratumumab (Darzalex, Indium In 111-DOTA-Daratumumab)

Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia · FRα

#FR#Antibody#Phase1#항체#면역항체+4
임상시험 2상태 RECRUITING
AntibodystaleTakedaPhase 2

Mezagitamab (Mezagitamab)

Relapsed and/or Refractory Multiple Myeloma (RRMM) · FRα

#FR#Antibody#Phase2#항체#면역항체+4
효능 ORR 25%임상시험 2상태 ACTIVE
AntibodystaleBeiGenePhase 3

Ociperlimab (Ociperlimab)

Advanced Hepatocellular Carcinoma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
효능 ORR 100%임상시험 2상태 DISCONTINUED
AntibodystaleXencor, Inc.Phase 1

XmAb541 (XmAb541)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase1#항체#면역항체+2
임상시험 2상태 RECRUITING
AntibodystalePETHEMA FoundationPhase 2

ibritumomab tiuxetan (ibritumomab tiuxetan)

Lymphoma · FRα

#FR#Antibody#Phase2#항체#면역항체+3
효능 ORR 89%임상시험 2상태 DISCONTINUED
AntibodySun Yat-sen UniversityPhase 2

Adebrelimab & SHR2554 (Adebrelimab & SHR2554)

Relapsed or Refractory Peripheral T Cell Lymphoma; NKTCL · FRα

#FR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodyRochePhase 2

Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib (Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib)

Platinum-sensitive Relapsed Ovarian Cancer · Platinum-sensitive Relapsed Ovarian Canc

#Platinum-sensitiveRelapsedOvaria#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleLei LiPhase 2

Albumin-bound paclitaxel and bevacizumab (Albumin-bound paclitaxel and bevacizumab)

Ovarian Carcinoma; Platinum-resistant Ovarian Cancer · Ovarian Carcinoma

#OvarianCarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Aribulin;carboplatin;bevacizumab (Aribulin;carboplatin;bevacizumab)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab + modified FOLFIRINOX (Bevacizumab + modified FOLFIRINOX)

Mucinous Ovarian Cancer; Fallopian Tube Cancer · Mucinous Ovarian Cancer

#MucinousOvarianCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab； HRS-1167 (Bevacizumab； HRS-1167)

Recurrent Ovarian Cancer · Recurrent Ovarian Cancer

#RecurrentOvarianCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleCompugen LtdPhase 1

nivolumab (Opdivo, COM701 with Opdivo, COM701 with Opdivo (Nivolumab).)

Advanced Cancer; Ovarian Cancer · Advanced Cancer

#AdvancedCancer#Antibody#Phase1#항체#면역항체+3
효능 ORR 6%임상시험 1상태 ACTIVE
AntibodystaleJanssenPhase 3

Daratumumab (CT-P44, CT-P44(Daratumumab))

Refractory or Relapsed Multiple Myeloma · FRα

#FR#Antibody#Phase3#항체#면역항체+3
임상시험 1상태 RECRUITING

2 / 5 페이지

← 이전다음 →